Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease
After the discovery of formoterol and salmeterol, new candidates for long-acting β2-
adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once …
adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once …
Ultra-Long-Acting β2-Adrenoceptor Agonists: An Emerging Therapeutic Option for Asthma and COPD?
MG Matera, M Cazzola - Drugs, 2007 - Springer
There has been a real interest recently in developing once-daily β2-adrenoceptor agonists
(ultra-long-acting β 2-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic …
(ultra-long-acting β 2-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic …
β2‐adrenoceptor agonists: current and future direction
M Cazzola, L Calzetta… - British journal of …, 2011 - Wiley Online Library
Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …
airway disorders, these agents are still central in the symptomatic management of asthma …
Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma
CG Lofdahl, KF Chung - European Respiratory Journal, 1991 - Eur Respiratory Soc
New long-acting beta 2-adrenoceptor agonists, formoterol and salmeterol, may soon appear
in several European countries for treatment of asthma. This review examines currently …
in several European countries for treatment of asthma. This review examines currently …
Novel long‐acting bronchodilators for COPD and asthma
M Cazzola, MG Matera - British journal of pharmacology, 2008 - Wiley Online Library
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD)
management and improving adherence with prescribed therapy is to reduce the dose …
management and improving adherence with prescribed therapy is to reduce the dose …
Long-Acting β2-Agonists in Asthma: Not so SMART?
GP Currie, DKC Lee, BJ Lipworth - Drug safety, 2006 - Springer
Asthma is a worldwide chronic disorder that is characterised by airway inflammation and
hyper-responsiveness, which results in intermittent airflow obstruction and subsequent …
hyper-responsiveness, which results in intermittent airflow obstruction and subsequent …
A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease
MP Sovani, CI Whale, AE Tattersfield - Drug Safety, 2004 - Springer
The two inhaled long-acting β 2-adrenoceptor agonists, salmeterol and formoterol, have
been studied extensively since their introduction in the early 1990s. In this review we …
been studied extensively since their introduction in the early 1990s. In this review we …
Pharmacology and therapeutics of bronchodilators
M Cazzola, CP Page, L Calzetta, MG Matera - Pharmacological Reviews, 2012 - ASPET
Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …
Long-acting β2-adrenoceptor agonists: a smart choice for asthma?
BJ Lipworth - Trends in pharmacological sciences, 2007 - cell.com
An endogenous defect in β 2-adrenoceptors that results in impaired relaxation of airway
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …
[HTML][HTML] Past, present and future—β2-adrenoceptor agonists in asthma management
The β-adrenoceptor agonists (β-agonists) have been used to relieve bronchoconstriction for
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …